By Habtamu W.
ADDIS ABABA Oct. 20 (EI) — Experts and regional stakeholders have called for concerted action to establish a robust, coordinated, and sustainable ecosystem for bioequivalence testing, ensuring that locally manufactured generic medicines across Eastern and Southern Africa are safe, accessible, and scientifically proven to protect public health and build true self-reliance.
They made the call as the Intergovernmental Authority on Development (IGAD), an East African bloc, convened a landmark five-day workshop in the Ethiopian capital, Addis Ababa, aiming to fast-track bioequivalence testing, harmonize regulatory frameworks, expand domestic testing capacity, eliminate costly overseas dependencies to guarantee the safety, quality, and therapeutic efficacy of essential generic medical products.
Held from Oct. 19 to 23, the workshop brought together national regulators, pharmaceutical manufacturers, academic researchers, and development partners, among others, to develop a comprehensive White Paper on bioequivalence testing capacity and regulatory harmonization.
A central objective of the workshop is to validate updated country-level findings concerning regulatory readiness, existing infrastructure, and implementation roadmaps. It also envisages to review international regulatory best practices, and identify critical technical, financial, and institutional barriers that currently hinder effective bioavailability and bioequivalence compliance across participating regional nations.
Workshop participants stressed that relying on external testing facilities imposes significant economic burdens and causes approval delays for locally manufactured generic medicines, making domestic testing expansion an urgent priority for sustainable pharmaceutical growth.
Addressing these critical operational hurdles requires tackling common regional constraints such as limited accredited testing centers, high study costs, acute shortages in specialized expertise, and inconsistent regulatory frameworks through coordinated risk-based responses and practical regional cooperation strategies.
Dr. Girum Hailu, senior policy and partnership specialist at IGAD, emphasized that robust bioequivalence ecosystems are essential for verifying that generic pharmaceutical products perform identically to comparator treatments, thereby safeguarding patient health and strengthening stakeholder trust in locally produced medicines.
Highlighting findings from a 2024 regional mapping exercise, Hailu noted that more than seven hundred locally manufactured products require bioequivalence data, yet very few submissions actually reach national regulators due to high costs and overseas testing dependence.

He further outlined four vital connected priorities for the workshop, which include validating country gaps, developing harmonized requirements for legacy products, prioritizing investment and accreditation for regional testing centers, and exploring collaborative pooled support mechanisms.
Experts at the workshop strongly urged local pharmaceutical manufacturers to actively map out product priorities, share testing requirements, and collaborate closely with regulatory authorities to achieve compliance and strengthen regional industrial competitiveness.
They further called on international development partners as well as regional economic communities to align technical assistance and financial investments with established priorities to ensure long-term operational sustainability across the region.
Armauer Hansen Research Institute Director General, Afework Kassu, stated that rapidly advancing national regulatory systems require accessible and reliable bioequivalence evidence to fully guarantee generic medicine quality and bolster public confidence in regulatory decisions.
Kassu highlighted that building sustainable regional capacity goes beyond simply constructing laboratories, requiring instead a coordinated and scientifically robust ecosystem that tightly links regulatory bodies, research centers, and pharmaceutical manufacturers around shared priorities.

The workshop emphasized that regional progress relies heavily on building upon existing capabilities, sharing professional expertise, and investing according to demonstrated needs to successfully overcome current testing limitations.
Concerned stakeholders were also urged to move beyond identifying gaps and instead commit to realistic priorities, clear responsibilities, and a sequenced implementation roadmap to achieve long-term sustainable pharmaceutical self-reliance.
The five-day regional gathering is expected to yield a comprehensive common regional strategy specifically designed to successfully strengthen bioavailability and bioequivalence testing capacity throughout the vast Eastern and Southern African region over coming years.
It further envisaged to bolster strategic investments in regional accredited testing facilities, aiming to significantly reduce the region’s heavy reliance on overseas testing and substantially improve overall access to safe and effective medical products.

















